Evidence map›Paper›PMID 42747695›Full record

ArticleTargeted oncology2026

Outcomes by Body Mass Index in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin.

Wendy Stock, Ryan D Cassaday, Daniel J DeAngelo, Anjali Advani, Nicola Gokbuget, Josep Ribera, Wei Jiang, Susana Pulido, Erik Vandendries, Nathan Braniff and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Targeted oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wendy StockDivision of Biological Sciences, University of Chicago, 5841 S Maryland Avenue, Chicago, IL, 60637, USA. wstock@bsd.uchicago.edu.ORCID http://orcid.org/0000-0002-8349-9200
Ryan D CassadaySchool of Medicine &, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Daniel J DeAngeloDana-Farber Cancer Institute, Boston, MA, USA.
Anjali AdvaniCleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
Nicola GokbugetDept. of Medicine II, Goethe University, University Hospital, Frankfurt, Germany.
Josep RiberaInstitut Català d' Oncologia &, Josep Carreras Leukaemia Research Institute, Badalona, Spain.
Wei JiangPfizer Inc, New York, NY, USA.
Susana PulidoPfizer Spain, Madrid, Spain.
Erik VandendriesPfizer Inc, Cambridge, MA, USA.
Nathan BraniffPfizer Inc, San Diego, CA, USA.
Elias JabbourThe University of Texas MD Anderson, Houston, TX, USA.
Hagop KantarjianThe University of Texas MD Anderson, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInotuzumab ozogamicin (lnO) is approved for the treatment of adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Elevated body mass index (BMI) could be associated with worse outcomes.

objectiveTo conduct post hoc BMI-stratified efficacy/safety analyses of lnO. PATIENTS AND

methodsPooled data from phase 1-4 InO trials were analyzed, with patients grouped by BMI: < 25 kg/m

resultsAcross 338 patients, complete remission (CR) or CR with incomplete count recovery (CRi) was achieved in 69.7%, 75.9%, 68.7%, and 84.6% patients in the < 25, 25-30, > 30, and > 40 kg/m

conclusionEfficacy/safety outcomes with InO were consistent across BMI subgroups. Dose-capping does not appear to be required.

Identifiers

PMID42747695

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.